ABBV

AbbVie Inc.

150.26
USD
-2.30%
150.26
USD
-2.30%
105.56 175.91
52 weeks
52 weeks

Mkt Cap 271.79B

Shares Out 1.77B

Chat
Send me real-time posts from this site at my email

AbbVie submits NDA for Parkinson's disease treatment

A phase 3 trial showed statistically significant improvement with ABBV-951 in terms of "on" time without troublesome dyskinesia compared to oral immediate-release carbidopa/levodopa. AbbVie noted that ABBV-951 would provide continuous, subcutaneous delivery over 24 hours. The company plans additional regulatory submissions for the candidate in international markets throughout the year. Read why Seeking Alpha contributor Jonathan Weber says that AbbVie (ABBV) is a hold.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue